Celgene (CELG) delivered a strong first-quarter earnings report Friday and a regulatory update on its delayed multiple sclerosis drug that took the worst-case scenario off the table.
The beleaguered biotech hasn’t fixed all its problems quite yet, but Friday’s business update didn’t give investors another reason to hate them, so it feels like a win. Shares of Celgene were up 3 percent to $87.70 in morning trading.
About the Author Reprints
we need a hit and perhaps some executive salary reductions due to very poor business decisions,i.e. the buying of companies with better promises and poor results.